# Tumor Grade Determines PD-1/PDL-1 Expression

> **NCT04528940** · — · UNKNOWN · sponsor: **RWJ Barnabas Health at Jersey City Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PD-1/PDL-1 staining

## Key facts

- **NCT ID:** NCT04528940
- **Lead sponsor:** RWJ Barnabas Health at Jersey City Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-25
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04528940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04528940, "Tumor Grade Determines PD-1/PDL-1 Expression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04528940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*